Early HER2 dysregulation in gastric and oesophageal carcinogenesis
- 15 March 2012
- journal article
- Published by Wiley in Histopathology
- Vol. 61 (5) , 769-776
Abstract
Fassan M, Mastracci L, Grillo F, Zagonel V, Bruno S, Battaglia G, Pitto F, Nitti D, Celiento T, Zaninotto G, Fiocca R & Rugge M (2012) Histopathology 61, 769–776Early HER2 dysregulation in gastric and oesophageal carcinogenesisAims: To explore human epidermal growth factor receptor 2 (HER2) status in the histological phenotypes [metaplasia, intraepithelial neoplasia (IEN, i.e. dysplasia), and adenocarcinoma] involved in the morphogenesis of both intestinal‐type gastric cancer (GC) and Barrett’s adenocarcinoma (BAc).Methods and results: A consecutive series of 275 samples of stomach and oesophagus tissue (representing the whole spectrum of the phenotypic changes involved in gastric and Barrett’s carcinogenesis) was studied. HER2 status was assessed by applying two immunohistochemistry (IHC) protocols, using the antibodies 4B5 and CB11. Dual‐colour silver chromogenic in‐situ hybridization (SISH) was also performed on the same tissue samples. In both oesophageal and gastric samples, the rate of HER2 overexpression rose significantly from low‐grade to high‐grade IEN to adenocarcinoma (P < 0.001), with the two IHC protocols showing consistent staining (consistency 95%; k = 0.78; P < 0.001). Intratumour heterogeneity was documented in both GC and BAc (using both IHC protocols). The rate of HER2 amplification (using SISH) increased significantly along with IEN dedifferentiation (P < 0.001). Neither native nor metaplastic mucosa samples (obtained from either stomach or oesophagus) ever showed HER2 amplification. There was excellent agreement between HER2 amplification and protein overexpression (both IHC protocols: SISH/4B5––consistency 97.8%, k = 0.89, P < 0.001; SISH/CB11—consistency 97.8%, k = 0.91, P < 0.001).Conclusions: There is early involvement of HER2 dysregulation (amplification and protein overexpression) in both gastric (intestinal‐type) and Barrett’s oncogenesis.Keywords
This publication has 27 references indexed in Scilit:
- Epithelial–mesenchymal transition in malignant mesotheliomaLaboratory Investigation, 2012
- Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinomaHistopathology, 2011
- Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization methodHistopathology, 2011
- HER2 amplification, overexpression and score criteria in esophageal adenocarcinomaLaboratory Investigation, 2011
- HER2 status in gastro‐oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH)Histopathology, 2011
- miRNAs in precancerous lesions of the gastrointestinal tractWorld Journal of Gastroenterology, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- TOPOIIα and HER‐2/neu overexpression/amplification in Barrett’s oesophagus, dysplasia and adenocarcinomaHistopathology, 2010
- Pathology of Gastric Intestinal Metaplasia: Clinical ImplicationsAmerican Journal of Gastroenterology, 2010
- Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotypeJournal of Clinical Pathology, 2007